Welcome to the international HTA database

Showing [20542 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2013	Agency for Healthcare Research and Quality (AHRQ)	Update on emerging genetic tests currently available for clinical use in common cancers
2011	Agency for Healthcare Research and Quality (AHRQ)	Update on horizon scans of genetic tests currently available for clinical use in cancers
2012	Agency for Healthcare Research and Quality (AHRQ)	Update on mapping the landscape of genetic tests for non-cancer diseases/conditions
2014	Health Quality Ontario (HQO)	Update on physiotherapy rehabilitation after total knee or hip replacement
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Update PET/PET-CT evidence for need based planning in the area of oncology
2003	Wessex Institute for Health Research and Development (WIHRD)	Update report: Effects of desensitisation treatments and clinical ecology for multiple chemical sensitivity and related disorders
2002	Wessex Institute for Health Research and Development (WIHRD)	Update report: Non-myeloablative bone marrow and peripheral blood stem cell transplant
2018	Center for Evidence-based Practice (CEP)	Update: Anticoagulation Management in Paracentesis and Thoracentesis
2018	Center for Evidence-based Practice (CEP)	Update: Best practices for central venous catheter removal
2023	Center for Evidence-based Practice (CEP)	Update: Clinical risk prediction tools for venous thromboembolism in medical patients
2014	Center for Evidence-based Practice (CEP)	Update: Cognitive and procedural skills of aging physicians
2017	NIHR Health Services and Delivery Research programme	Updated meta-review of evidence on support for carers
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Updated reports and recommendations on second- and third-line therapies for type 2 diabetes
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: Alair® bronchial thermoplasty system for severe asthma
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: Amniotic fluid lactate™ monitoring system for dysfunctional labour
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: Argus II™ retinal prosthesis system for peripheral retinal degeneration
2013	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: Caris Target Now™ molecular profiling service for solid malignant tumours
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: DuoFertility ovulation prediction system to aid natural conception
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: Infrared lasers for treating onychomycosis
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: OVA1™ test for the assessment of suspected ovarian cancer
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: Placental growth factor based tests for the diagnosis of pre-eclampsia
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: RealTime mS9 Colorectal Cancer (CRC) Assay for the early detection of colorectal cancer
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: RhinoChill® intranasal cooling device for protective cooling the brain after a cerebral ischaemic event
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: SoundBite™ hearing system
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: SpringTMS™ Total Migraine System
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: ThromboLUX™ for determining platelet quality
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: VERV™ patient managed transdermal neuromodulation system for overactive bladder syndrome
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: Xpert MTB/RIF® test for tuberculosis
2007	Agency for Healthcare Research and Quality (AHRQ)	Updating systematic reviews
2016	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Upper airway stimulation for moderate-to-severe sleep apnea
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Upper Airway Stimulation for Moderate-to-Severe Sleep Apnea. 1st Update 2019
2022	Austrian Institute for Health Technology Assessment (AIHTA)	Upper airway stimulation for moderate-to-severe sleep apnoea. Update 2022
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Upper extremity deep vein thrombosis with peripherally inserted central catheters: a review of the guidelines
2008	HAYES, Inc.	Upright magnetic resonance imaging (MRI) for diagnosis of spinal disorders
2014	HAYES, Inc.	Upright magnetic resonance imaging for diagnosis of spinal disorders
2005	Institute for Clinical Evaluative Sciences (ICES)	Uptake and outcomes associated with cyclooxygenase (COX-2) inhibitors in Ontario's elderly
1997	Scottish Health Purchasing Information Centre (SHPIC)	Uptake of breast cancer screening
2011	Institute for Clinical Evaluative Sciences (ICES)	Uptake of the new fee code for Ontario's enhanced 18-month well baby visit: a preliminary evaluation
1998	ECRI	Urea breath tests for detecting helicobacter pylori
2007	HAYES, Inc.	Ureteral bulking agents for vesicoureteral reflux disease
2014	Center for Evidence-based Practice (CEP)	Urinalysis and urine culture specimens taken from old versus new urinary catheters in patients with suspected urinary tract infection
2010	HAYES, Inc.	Urinary cross-linked N-telopeptide of type I collagen biomarker for diagnosis of osteoporosis and fracture risk assessment
2010	HAYES, Inc.	Urinary cross-linked N-telopeptide of type I collagen biomarker for management of osteoporosis treatment
2001	Health Council of the Netherlands Gezondheidsraad (GR)	Urinary incontinence - review, expert panel
2006	National Institute for Health and Clinical Excellence (NICE)	Urinary incontinence: the management of urinary incontinence in women
2008	Medical Services Advisory Committee (MSAC)	Urinary metabolic profile
2008	Medical Services Advisory Committee (MSAC)	Urinary metabolic profiling for detection of metabolic disorders
2009	Canadian Agency for Drugs and Technologies in Health (CADTH)	Urine based testing for gonorrhea and chlamydia: a review of diagnostic accuracy, cost-effectiveness, and compliance
2013	Center for Evidence-based Practice (CEP)	Urine drug screening in chronic pain patients on opioid therapy
2010	Center for Evidence-based Practice (CEP)	Urine drug screening in chronic pain patients on opioid therapy
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Urine testing in long-term care: clinical and cost effectiveness
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Urine testing in long-term care: guidelines
2020	NIHR Health Technology Assessment programme	Urodynamics tests for the diagnosis and management of bladder outlet obstruction in men: the UPSTREAM non-inferiority RCT
2017	HAYES, Inc.	Urolift system (NeoTract Inc.) for treatment of benign prostatic hyperplasia
2016	HAYES, Inc.	UroLift System (NeoTract Inc.) for treatment of benign prostatic hyperplasia
2011	HAYES, Inc.	UroLume urethral stent (American Medical Systems Inc.) for urinary obstruction secondary to benign prostatic hyperplasia (BPH)
2016	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Ursodeoxycholic acid (Ursofalk®)
2020	Agency for Care Effectiveness (ACE)	Ursodeoxycholic acid for treating primary biliary cirrhosis
2020	NIHR Health Technology Assessment programme	Ursodeoxycholic acid to reduce adverse perinatal outcomes for intrahepatic cholestasis of pregnancy: the PITCHES RCT
2006	Adelaide Health Technology Assessment (AHTA)	USCOM cardiac output monitor for patients requiring haemodynamic monitoring
2005	Adelaide Health Technology Assessment (AHTA)	USCOM cardiac output monitor for ultrasonic cardiac output measurement in patients requiring haemodynamic monitoring
2006	Alberta Heritage Foundation for Medical Research (AHFMR)	USCOM for cardiac output monitoring
2007	Adelaide Health Technology Assessment (AHTA)	USCOM: Ultrasound cardiac output monitor for patients requiring haemodynamic monitoring
2006	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Use of adalimumab (Humira®) within NHS Wales
2006	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Use of agalsidase beta (Fabrazyme®) within NHS Wales
2007	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Use of alglucosidase alfa (Myozyme™) within NHS Wales
2010	HAYES, Inc.	Use of anti-infliximab antibody levels to monitor infliximab treatment
2013	HAYES, Inc.	Use of anti-infliximab antibody levels to monitor infliximab treatment in patients with inflammatory bowel disease (IBD)
2015	HAYES, Inc.	Use of anti-infliximab antibody levels to monitor infliximab treatment in patients with inflammatory bowel disease (IBD)
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Use of anti-neuronal antibodies to diagnose paraneoplastic neurological syndromes
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Use of antipsychotics and/or benzodiazepines as rapid tranquilization in inpatients of mental facilities and emergency departments: a review of the clinical effectiveness and guidelines
2005	Health Council of the Netherlands Gezondheidsraad (GR)	Use of antiviral agents and other measures in an influenza pandemic
2011	Medical Services Advisory Committee (MSAC)	Use of artificial disc replacement in patients with cervical degenerative disc disease
2007	Agency for Healthcare Research and Quality (AHRQ)	Use of aspirin and NSAIDs to prevent colorectal cancer; an evidence synthesis
2005	Medical Advisory Secretariat (MAS)	Use of automated external defibrillators in cardiac arrest - health technology literature review
2005	Medical Advisory Secretariat (MAS)	Use of automated external defibrillators in cardiac arrest: an evidence-based analysis
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Use of azathioprine in adults: safety
2021	Ontario Health	Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart Failure
2009	Agency for Healthcare Research and Quality (AHRQ)	Use of Bayesian techniques in randomized clinical trials: a CMS case study
2016	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Use of biventricular pacing in atrioventricular heart block
2005	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Use of Bortezomib (Velcade®) within NHS Wales
2007	Agency for Health Technology Assessment in Poland (AHTAPol)	Use of bosentan, epoprostenol, iloprost, sildenafil and treprostinil in treatment of pulmonary arterial hypertension in Poland. Budget impact analysis.
2001	Health Technology Advisory Committee (HTAC)	Use of botulinum toxin-A in pain associated with neuromuscular disorders
2003	Institute for Clinical Effectiveness and Health Policy (IECS)	Use of botulinum toxine in the clinical practice
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Use of bupropion in patients with depression and the associated risk of seizures: safety
1995	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	Use of calcitonin in idiopathic osteoporosis
2004	Alberta Heritage Foundation for Medical Research (AHFMR)	Use of cannabis or cannabinoids for non-malignant chronic pain
2015	Agency for Healthcare Research and Quality (AHRQ)	Use of cardiac resynchronization therapy in the Medicare population
2004	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Use of carmustine implants (GLIADEL wafer) in patients with malignant glioma at The McGill University Health Centre
1998	Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT)	Use of CDET gamma-cameras for conventional scintigraphy (systematic review, primary research, expert panel)
2006	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Use of cetuximab (Erbitux®) within NHS Wales
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Use of chlorhexidine gluconate with alcohol for the prevention of peripheral intravenous device infections: a review of clinical and cost effectiveness, and guidelines
2000	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Use of cisapride in patients with non-ulcer dyspepsia: a meta-analysis of randomized trials
2008	Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS)	Use of class 3b and class 4 lasers and intense pulsed light sources for cosmetic procedures in non-medical settings
2009	NIHR Health Technology Assessment programme	Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review
2009	NIHR Health Technology Assessment programme	Use of classical and novel biomarkers as prognostic risk factors for prostate cancer: a systematic review
2010	Medical Advisory Secretariat (MAS)	Use of contrast agents with echocardiography in patients with suboptimal echocardiography
2014	Blue Cross Blue Shield Association (BCBS)	Use of digital breast tomosynthesis with mammography for breast cancer screening or diagnosis
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Use of diuretics for hypertension in patients with reduced renal function: a review of clinical effectiveness, safety, and guidelines
2015	NIHR Health Technology Assessment programme	Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre, placebo-controlled, randomised controlled trial and cost-effectiveness analysis of a calcium channel blocker (nifedipine) and an alpha-blocker (tamsulosin) (the SUSPEND trial)